Korean Red Ginseng exhibits no significant adverse effect on disease activity in patients with rheumatoid arthritis: a randomized, double-blind, crossover study

Soo-Kyung Cho, Dam Kim, Dasomi Yoo, Eun Jin Jang, Jae-Bum Jun, Yoon-Kyoung Sung, Soo-Kyung Cho, Dam Kim, Dasomi Yoo, Eun Jin Jang, Jae-Bum Jun, Yoon-Kyoung Sung

Abstract

Background: Panax ginseng is a well-known immune modulator, and there is concern that its immune-enhancing effects may negatively affect patients with rheumatoid arthritis (RA) by worsening symptoms or increasing the risk of adverse effects from other drugs. In this randomized, crossover clinical trial, we evaluated the impact of Korean Red Ginseng (KRG) on disease activity and safety in RA patients.

Methods: A total of 80 female RA patients were randomly assigned to either the KRG (2 g/d, n = 40) treatment or placebo (n = 40) groups for 8 wk, followed by crossover to the other treatment group for an additional 8 wk. The primary outcome was the disease flare rate, defined as worsening disease activity according to the disease activity score 28 joints-erythrocyte sedimentation rate (DAS28-ESR). The secondary outcomes were development of adverse events (AEs) and patient reported outcomes. Outcomes were evaluated at baseline and 8 wk and 16 wk. The outcomes were compared using the Chi-square test.

Results: Of the 80 patients, 70 completed the full study. Their mean age was 51.9 yr, and most exhibited low disease activity (mean DAS28-ESR 3.5 ± 1.0) at enrollment. After intervention, the flare rate was 3.7% in each group. During KRG treatment, 10 AEs were reported, while five AEs were developed with placebo; however, this difference was not statistically significant (p = 0.16). Gastrointestinal- and nervous system-related symptoms were frequent in the KRG group.

Conclusion: KRG is not significantly associated with either disease flare rate or the rate of AE development in RA patients.

Keywords: Korean Red Ginseng; effect; rheumatoid arthritis; safety.

Figures

Fig. 1
Fig. 1
Study design.

References

    1. Gabriel S.E. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269–281.
    1. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–916.
    1. Whalley D., McKenna S.P., de Jong Z., van der Heijde D. Quality of life in rheumatoid arthritis. Br J Rheumatol. 1997;36:884–888.
    1. Alvarez-Hernández E., César Casasola-Vargas J., Lino-Pérez L., Burgos-Vargas R., Vázquez-Mellado J. Complementary and department for the first time. Analysis of 800 patients. Reumatol Clin. 2006;2:183–189. [Article in Spanish]
    1. Setty A.R., Sigal L.H. Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin Arthritis Rheum. 2005;34:773–784.
    1. Efthimiou P., Kukar M. Complementary and alternative medicine use in rheumatoid arthritis: proposed mechanism of action and efficacy of commonly used modalities. Rheumatol Int. 2010;30:571–586.
    1. Ramos-Remus C., Raut A. Complementary and alternative practices in rheumatology. Best Pract Res Clin Rheumatol. 2008;22:741–757.
    1. Han M., Sung Y.K., Cho S.K., Kim D., Won S., Choi C.B., Bang S.Y., Cha H.S., Choe J.Y., Chung W.T. Factors associated with the use of complementary and alternative medicine for Korean patients with rheumatoid arthritis. J Rheumatol. 2015;42:2075–2081.
    1. Kiefer D., Pantuso T. Panax ginseng. Am Fam Physician. 2003;68:1539–1542.
    1. Choi S., Kim T., Shin Y., Lee C., Park M., Lee H., Song J. Effects of a polyacetylene from Panax ginseng on Na(+) currents in rat dorsal root ganglion neurons. Brain Res. 2008;29:75–83.
    1. Na J.Y., Kim S., Song K., Lim K.H., Shin G.W., Kim J.H., Kim B., Kwon Y.B., Kwon J. Anti-apoptotic activity of ginsenoside Rb1 in hydrogen peroxide-treated chondrocytes: stabilization of mitochondria and the inhibition of caspase-3. J Ginseng Res. 2012;36:242–247.
    1. Choi Y.S., Kang E.H., Lee E.Y., Gong H.S., Kang H.S., Shin K., Lee E.B., Song Y.W., Lee Y.J. Joint-protective effects of compound K, a major ginsenoside metabolite, in rheumatoid arthritis: in vitro evidence. Rheumatol Int. 2013;33:1981–1990.
    1. Kim H.A., Kim S., Chang S.H., Hwang H.J., Choi Y.N. Anti-arthritic effect of ginsenoside Rb1 on collagen induced arthritis in mice. Int Immunopharmacol. 2007;7:1286–1291.
    1. Jhun J., Lee J., Byun J.K., Kim E.K., Woo J.W., Lee J.H., Kwok S.K., Ju J.H., Park K.S., Kim H.Y. Red ginseng extract ameliorates autoimmune arthritis via regulation of STAT3 pathway, Th17/Treg balance, and osteoclastogenesis in mice and human. Mediators Inflamm. 2014;2014:351856.
    1. Prevoo M.L., van Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–48.
    1. Cella D., Yount S., Sorensen M., Chartast E., Sengupta N., Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol. 2005;32:811–819.
    1. Bae S.C., Cook E.F., Kim S.Y. Psychometric evaluation of a Korean Health Assessment Questionnaire for clinical research. J Rheumatol. 1998;25:1975–1979.
    1. Kim M.H., Cho Y.S., Uhm W.S., Kim S., Bae S.C. Cross cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases. Qual Life Res. 2005;14:1401–1406.
    1. Kang S., Min H. Ginseng, the 'Immunity Boost': the effects of Panax ginseng on immune system. J Ginseng Res. 2012;36:354–368.
    1. Hwang I., Ahn G., Park E., Ha D., Song J.Y., Jee Y. An acidic polysaccharide of Panax ginseng ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells. Immunol Lett. 2011;138:169–178.
    1. Kim Y., Kim S., Markelonis G., Oh T. Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration. Neurosci Res. 1998;54:123.
    1. Radad K., Gille G., Liu L., Rausch W. Use of ginseng in medicine with emphasis on neurodegenerative disorders. J Pharmacol Sci. 2006;100:175–186.
    1. Shin Y., Jung O., Nah J., Nam K., Kim C., Nah S. Ginsenosides that produce differential antinociception in mice. Gen Pharmacol. 1999;32:653–659.
    1. Rhim H., Kim H., Lee D., Oh T., Nah S. Ginseng and ginsenoside Rg3, a newly identified active ingredient of ginseng, modulate Ca2+ channel currents in rat sensory neurons. Eur J Pharmacol. 2002;436:151–158.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅